Chesnara half-year results 2026: OCG jumps 79% as dividend rises 6%

Chesnara PLC has reported a sharp increase in capital generation for the first half of 2026, helped by its newly acquired UK life insurance business.

Operating Capital Generation rose 79% to £96 million, cash remittances increased 31% to £73 million and adjusted operating profit climbed 46% to £31 million.

The board also declared a 6% increase in the interim dividend to 8.16p per share. However, investors should note that the uplift includes a one-off additional 3% step-up, rather than necessarily establishing a new annual growth rate.

The headline figures are strong, but they require some unpacking. A substantial portion of capital generation came from acquisition-related impacts and management actions, while Chesnara's solvency ratio fell following the completion of its largest acquisition to date.

Chesnara's key half-year figures

Metric	H1 2026	Comparator	Change
Operating Capital Generation	£96 million	£54 million	79%
Cash remittances	£73 million	£56 million	31%
Adjusted operating profit	£31 million	£21 million	46%
Solvency coverage ratio	185%	257% at FY 2025	Down 72 percentage points
Own Funds	£976 million	£859 million at FY 2025	14%
Assets under Administration	£21 billion	£15 billion at FY 2025	38%
New Business Contribution	£12 million	£5 million	152%
Interim dividend	8.16p	Prior-year interim dividend not directly stated	6%

Operating Capital Generation, or OCG, measures the Solvency II capital produced through operational activity. This matters because capital supports Chesnara's dividends, debt obligations and ability to make further acquisitions.

Cash remittances are the payments made by the operating businesses to the group centre, where shareholder dividends and central costs are funded.

Acquisitions drove much of the growth

Chesnara completed its acquisition of HSBC Life (UK) in January 2026 and subsequently renamed the business Chesnara Life UK. It is the company's largest transaction so far and added around £5 billion of assets under administration.

The acquired business contributed for five months of the reporting period and helped lift the UK division's OCG from £29 million to £64 million. UK adjusted operating profit increased from £14 million to £20 million.

However, £51 million of the group's £96 million OCG related to acquisition impacts and capital optimisation activity concerning Chesnara Life UK. A further £12 million came from capital optimisation measures elsewhere in the group.

That leaves £33 million from underlying surplus emergence across the business units. In plain English, the majority of the headline OCG was not simply recurring organic growth from the existing portfolio.

This does not make the capital generation less real, but it does mean investors should be careful when using the 79% increase as a guide to future growth.

Management has used reinsurance, foreign exchange hedging and tax-related capital relief to improve capital efficiency. These actions can strengthen the balance sheet, although they also make the results more dependent on alternative performance measures and actuarial assumptions.

The solvency ratio fell, but remains above target

Chesnara's solvency coverage ratio declined from 257% at the end of 2025 to 185% at 30 June 2026.

The reduction largely reflects the purchase price and additional capital requirements associated with Chesnara Life UK. The acquisition itself reduced the ratio by 147 percentage points, while operating capital generation added 73 percentage points.

A solvency ratio compares the capital available to an insurer with its regulatory capital requirement. A figure above 100% means the insurer holds more capital than the regulatory minimum.

Although the fall looks dramatic, 185% remains above Chesnara's operating range of 140% to 160%. It was also five percentage points ahead of the company's previous pro-forma estimate of approximately 180%.

Management expects the ratio to remain above the top of its operating range after the proposed Scottish Widows Europe acquisition completes. That gives Chesnara continued capacity to consider further transactions, although the capital cushion is clearly lower than it was before the HSBC deal.

Adjusted profit improved, but statutory earnings need context

Adjusted operating profit increased by 46% to £31 million, supported by operating performance and the contribution from Chesnara Life UK.

On an IFRS basis, profit before tax was £61 million, compared with a £5 million loss in the first half of 2025. Profit after tax was only £0.6 million, however, primarily because the £60.4 million tax expense largely represented UK policyholder tax linked to positive investment growth.

Integration and restructuring costs totalled £23 million, up from £15 million. These included spending connected with Chesnara Life UK and the proposed Scottish Widows Europe deal.

The distinction matters because Chesnara relies heavily on alternative performance measures such as OCG and adjusted operating profit. These can be useful for understanding an insurer, but investors should consider them alongside the statutory accounts rather than in isolation.

Dividend rises 6%, including a one-off boost

The interim dividend has increased by 6% to 8.16p per share and is expected to be paid on 16 October 2026.

The shares are due to trade ex-dividend on 3 September, with a record date of 4 September.

Chesnara says this will be its 22nd consecutive year of increasing shareholder returns. That record remains an important feature of the investment case.

Still, half of this year's percentage increase is described as a one-off additional step-up linked to confidence in the acquisitions and first-half performance. Investors should therefore avoid assuming that 6% dividend growth will automatically continue.

Scottish Widows Europe is the next major milestone

Chesnara's proposed acquisition of Scottish Widows Europe is expected to add approximately €1.7 billion of assets under administration, around 46,000 policies and €250 million of cash generation over the portfolio's lifetime.

The deal would also establish a presence in Luxembourg, providing a base for further European consolidation.

The regulatory change-of-control application has been submitted, with completion anticipated around the end of 2026. This timetable remains subject to regulatory approval, so the expected benefits are not yet secured.

Meanwhile, the migration of Chesnara Life UK systems data to SS&C remains scheduled for completion by the end of 2026. The associated legal transfer is expected to follow in 2027.

What investors should watch next

The results show that Chesnara's acquisition strategy is materially increasing its scale. Assets under administration reached £21 billion and the group now oversees approximately 1.3 million policies.

The positives are stronger cash remittances, a solvency ratio above target, higher adjusted profit and another dividend increase. Chesnara Life UK is also generating capital relatively early in its ownership.

The main cautions are the acquisition-heavy composition of OCG, £23 million of integration and restructuring costs, weaker OCG in Sweden and the Netherlands, and the execution risk attached to several integration programmes.

Swedish OCG fell from £8 million to £3 million following adverse policy retention experience, while Dutch OCG declined from £15 million to £7 million following adverse mortality experience and a tougher prior-year comparison.

The key test is whether Chesnara can convert its enlarged scale into repeatable capital generation after the acquisition benefits and optimisation actions settle down. Progress on the SS&C migration, regulatory approval for Scottish Widows Europe and the composition of second-half OCG should provide useful evidence.

The full figures and accompanying disclosures are available in the original company announcement.